Who
Jason B. Daly
EVP, Chief Legal Officer
Company insider
Files Form 4 as: EVP, Chief Legal Officer, Amneal Pharmaceuticals.
In numbers
- Trades disclosed
- 72
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $9.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 3 Mar 2022
- Last trade
- 12 Aug 2026
- Last filed
- 13 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Aug 2026filed 13 Aug 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $3.7M210,000 at $17.40 | filing |
| 12 Aug 2026filed 13 Aug 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $3.7M210,000 at $17.40 | filing |
| 11 Aug 2026filed 13 Aug 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $117K6,613 at $17.70 | filing |
| 11 Aug 2026filed 13 Aug 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $117K6,613 at $17.70 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $207K15,580 at $13.30 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —35,880 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —35,880 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —35,880 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $207K15,580 at $13.30 | filing |
| 4 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —35,880 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —22,645 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —22,645 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —38,226 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —24,258 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —305,810 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $135K10,147 at $13.31 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —38,226 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —22,645 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —38,226 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | AMRX Amneal Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —24,258 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.